Speciality: Cardiology
Description:
.A warm welcome to all the medical professionals in this interesting live Session on Transthyretin Amyloid Cardiomyopathy (ATTR-CM) by Pfizer.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a progressive and often underdiagnosed condition characterized by the deposition of abnormal transthyretin protein in the heart tissue. Pfizer, a leading pharmaceutical company, is at the forefront of research and development in the field of ATTR-CM.
Through innovative therapies and groundbreaking clinical trials, Pfizer aims to improve the diagnosis, management, and outcomes for patients affected by this debilitating disease. With a commitment to advancing medical science and enhancing patient care, Pfizer's efforts in the field of ATTR-CM offer hope for those living with this challenging condition.
Therefore, get an overall knowledge on detecting fetal aneuploidies in maternal blood. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions
See More Webinars @ Hidoc Webinars
1.
Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.
2.
More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.
3.
What Role Should Genomic Classifier Testing Play in Prostate Cancer?
4.
A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma
5.
Squeezing through tiny blood vessels may trigger melanoma cells to spread
1.
The Future of Cancer Care: Genetics, Support Systems, and Emerging Therapies
2.
Everything You Need to Know About Leiomyomas: A Comprehensive Guide
3.
The Importance of Corrected Calcium Levels in Managing Health Conditions
4.
How Parvovirus B19 Affects Pregnant Women and Their Unborn Babies
5.
Cowden Syndrome and Cancer: Understanding the Risk Factors
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
3.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation